Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza.
Front Immunol. 2021 Jun 10;12:678483. doi: 10.3389/fimmu.2021.678483. eCollection 2021.
Front Immunol. 2021.
PMID: 34177921
Free PMC article.
Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.
Leroux-Roels I, Waerlop G, Tourneur J, De Boever F, Maes C, Bruhwyler J, Guyon-Gellin D, Moris P, Del Campo J, Willems P, Leroux-Roels G, Le Vert A, Nicolas F.
Leroux-Roels I, et al. Among authors: guyon gellin d.
Front Immunol. 2022 Apr 7;13:852904. doi: 10.3389/fimmu.2022.852904. eCollection 2022.
Front Immunol. 2022.
PMID: 35464450
Free PMC article.
Clinical Trial.
Item in Clipboard
OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model.
Primard C, Monchâtre-Leroy E, Del Campo J, Valsesia S, Nikly E, Chevandier M, Boué F, Servat A, Wasniewski M, Picard-Meyer E, Courant T, Collin N, Salguero FJ, Le Vert A, Guyon-Gellin D, Nicolas F.
Primard C, et al. Among authors: guyon gellin d.
Front Immunol. 2023 Jun 19;14:1188605. doi: 10.3389/fimmu.2023.1188605. eCollection 2023.
Front Immunol. 2023.
PMID: 37409116
Free PMC article.
Item in Clipboard
Cite
Cite